| ¿µ¹® | glia cell | ÇÑ±Û | ¾Æ±³¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ½Å°æ¼¼Æ÷ »çÀÌ¿¡¼ ±×¹°±¸Á¶¸¦ ÀÌ·ç¸ç À̸¦ ÁöÁöÇÏ´Â Á¶Á÷. ½Å°æ¾Æ±³¼¼Æ÷´Â ½Å°æ¸ð¼¼Æ÷¿Í °¥¶óÁø ¾Æ±³¸ð¼¼Æ÷°¡ ´Ù½Ã ¿©·¯ ÇüÅ·ΠºÐÈ-¼ºÀåÇÑ °ÍÀÌ´Ù. ³ú½ÇÀ̳ª ô¼öÁ߽ɰüÀÇ º®À» µ¤°í ¿øÁÖ»ó ¶Ç´Â ÀÔ¹æÇüÀ̸ç, Ãʱ⿡´Â À¯¸®¸é¿¡ ¼¶¸ð°¡ ÀÖ´Ù. ´ëÇü¼¼Æ÷´Â º°³ú½Ç¸·¼¼Æ÷´Â ¾Æ±³¼¼Æ÷¶ó°í Çϸç, ½Å°æ¼¼Æ÷³ª ½Å°æ¼¶À¯ »çÀÌ¿¡ »êÀçÇÑ´Ù. ±× ¿Ü¿¡ Èñ¼Òµ¹±â¾Æ±³¼¼Æ÷µµ Æ÷ÇԵȴÙ. |
||
| ¿µ¹® | reserve cell | ÇÑ±Û | ¿¹ºñ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼ ÀÌ¹Ì ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇÏ¸é ¸Å²ãÁö´Â ±× ¹Ø¿¡ ÀÖ´Â ¹ÌºÐȼ¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ ÀÖ´Â ÀÛÀº ¹ÌºÐÈ »óÇÇ ¼¼Æ÷. |
||
| ¿µ¹® | renal cell carcinoma | ÇÑ±Û | ÄáÆÏ¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼ ¹ß»ýÇÑ ¾Ï. ÁÖ·Î ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸ÀÌ´Â ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈÇпä¹ýÀÌ¸ç ¾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù. |
||
| ¿µ¹® | squamous cell carcinoma | ÇÑ±Û | ÆíÆò¼¼Æ÷¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼, ÆíÆò¼¼Æ÷°¡ ÀÖ´Â ¾î¶² °÷¿¡¼µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀÚ±Ã¾Ï µîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. ƯÈ÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢ÈÁõ¿¡¼ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Ư¼ºÀ¸·Î¼ °¢ÁúÀ» »ý¼ºÇÑ´Ù. |
||
| PBSC | peripheral blood stem cell |
|---|---|
| PHSC | pleuripotent hemopoietic stem cell |
| PMSC | pediatric medical special care; pluripotent myeloid stem cell |
| PSCT | peripheral stem cell transplantation |
| SCF | Skin Cancer Foundation; stem cell factor; subcostal frontal [view] |
| Allo-PBSCT | Allogeneic peripheral blood stem cell transplantation |
|---|---|
| allo SCT | Allogeneic stem cell transplantation |
| ABSCT | Autologous Blood Stem Cell Transplantation |
| ASCT | Autologous Stem Cell Transplantation |
| APBSCT | Autologous peripheral blood stem cell transplantation |
| T-cell growth factor-2 | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |
|---|---|
| age factors | Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from aging, a physiological process, and time factors which refers only to the passage of time. (12 Dec 1998) |
| bacteriocin factors | Bacterial plasmid's responsible for the elaboration of bacteriocins. Synonym: bacteriocin factors, bacteriocinogens. (05 Mar 2000) |
| biological factors | Compounds made by living organisms. They have biological or physiological activities. (12 Dec 1998) |
| biotic factors | Environmental factor's or influences resulting from the activities of living organisms, as contrasted to those resulting from climatic, geological, or other factor's. (05 Mar 2000) |
| blood coagulation factors | Endogenous substances, usually proteins, that participate in the blood coagulation process. (12 Dec 1998) |
| macrophage migration-inhibitory factors | Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. (12 Dec 1998) |
| recognition factors | Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites. (05 Mar 2000) |
| glaucoma, risk factors | If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites). (12 Dec 1998) |
| releasing factors | Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland. (09 Oct 1997) |
| resistance factors | Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter. Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes. (05 Mar 2000) |
| peptide elongation factors | Protein factors uniquely required during the elongation phase of protein synthesis. (12 Dec 1998) |
| peptide initiation factors | Protein factors uniquely required during the initiation phase of protein synthesis. (12 Dec 1998) |
| peptide termination factors | Proteins that are exclusively involved in the termination reactions of protein synthesis on the ribosome. (12 Dec 1998) |
| C factors | Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc. Synonym: C factors. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|